

This newsletter summarises final decisions from HTA bodies around the world from April 2024.

These decisions are categorised into one of four groups.

- *Decisions of HTA bodies are categorised according to the type of intervention into Pharmacological, Non-Pharmacological and Diagnostic.*
- *Statements from HTA bodies in the form of guidelines on the management of a disease using specific interventions are included under Other Guidance.*

Click on the category you are interested in to jump to that section

[Pharmacological
Technologies](#)

[Non-pharmacological
Technologies](#)

[Diagnostic
Tests](#)

[Other
Guidance](#)

Within each section the reports have been grouped according to clinical speciality. On the section contents page, there are shortcuts to each clinical speciality and specific report. All tiles are hyperlinked to the report file or to the HTA website.

Here we list a key for the decisions made by the HTA bodies for the reports listed in this newsletter:



The reporting document states that the technology has been approved.



The reporting document states that the technology has not been approved.



The report was terminated, additional details are provided under the icon.



The report was excluded because it is covered by another HTA body in that country.



This is where documentation cannot be translated or it is unclear on the reporting outcome.



This entry includes a note from the report relating to the technology.



This is for reports that do not report a decision but summarises the evidence for the technology.

Pharmacological Technologies

Blood



- Ferric derisomaltose – Brazil

Cancer




- Abiraterone, apalutamide, daralutamide, and enzalutamide - Brazil
- Abiraterone, apalutamide, daralutamide, and enzalutamide - Brazil
- Avapritinib - Germany
- Axicabtagene cilocleucel - France
- Cabozantinib with nivolumab - England
- Dabrafenib and trametinib - Wales
- Dostarlimab - Germany
- Dostarlimab - Scotland
- Dostarlimab - England
- Durvalumab - France
- Elranatamab - Germany
- Enzalutamide - Austria
- Erdafitinib - France
- Irinotecan hydrochloride trihydrate - Austria
- Ivosidenib - Wales
- Melphalan flufenamide - Wales
- Melphalan flufenamide with dexamethasone - England
- Olaparib - Brazil

Cancer




- Olaparib - France
- Pembrolizumab - France
- Pembrolizumab - France
- Pembrolizumab with gemcitabine and cisplatin - England
- Pembrolizumab - Wales
- Pembrolizumab - Germany
- Polatumab vedotin - Germany
- Polatumab vedotin - Germany
- Selpercatinib - France
- Selpercatinib - Austria
- Tisagenlecleucel - Wales

Cardiovascular




- Mavacamten - Scotland
- Riociguat - Brazil
- Sotatercept - France

Gastrointestinal



- Infliximab - Brazil
- Mirikizumab - Scotland

Infection



- Valganciclovir + ganciclovir - Brazil

Pharmacological Technologies



Metabolic/Genetic

- Empagliflozin - Germany
- Inotersen - Brazil
- Lomitapide - France
- Pegzilarginase - Germany
- Tirzepatide - Scotland
- Vamorolone - Germany



Musculoskeletal

- Ixekizumab - Brazil
- Ixekizumab - Brazil



Neurology

- Inebilizumab - Brazil
- Zilucoplan - France


Other

- Daridorexant - Scotland



Respiratory

- Glycopyrronium/ formoterol fumarate – Scotland



Skin


- Ritlecitinib - Scotland

Non-pharmacological Technologies



Cancer

- Epidermal radiotherapy with Rhenium-188 paste - England
- Low-temperature circulation method - South Korea
- Lymphovenous anastomosis – England



Cardiovascular

- 3D printed artificial blood vessel graft - South Korea
- Resuscitative Endovascular Balloon Occlusion - South Korea



Gastrointestinal

- Endoscopic Anti-Reflux Mucosectomy - South Korea



Genitourinary

- Diagnosis and management of endometriosis - England



Mental Health

- Light Therapy - Spain



Musculoskeletal

- GaitSmart rehabilitation exercise programme – England

Neurology



- Migraine surgery - South Korea

Other

- Portable Automated Sputum Suction - South Korea

Respiratory



- Digital pulmonary rehabilitation programmes - England

Diagnostic Technologies



Cancer

- Genomic test - Spain



Infection

- Kurin Lock - England



Musculoskeletal


- Fracture Sonography - Germany

Other Guidance



Cancer

- [177Lutetium PSMA radioligand therapy - Ireland](#)
- [Detection of mutations - Spain](#)



Cardiovascular

- [Coronary sinus reducer stent - Spain](#)
- [Renal denervation - Canada](#)



Metabolic/Genetic

- [Newborn screening - Spain](#)




Musculoskeletal

- [Fracture management - Spain](#)

Other

- [Cannabis - United States](#)



Skin

- [Omalizumab - Canada](#)

Pharmacological Technologies



Blood



Cancer

Brazil



Ferric derisomaltose

Population:
Adult

10 April 2024



Treatment of iron deficiency anaemia.

CONITEC

 **APPROVED**

Brazil



Abiraterone, apalutamide, daralutamide, and enzalutamide

Population:
Adult

11 April 2024



Treatment of metastatic castration-sensitive prostate cancer (mCSPC).

CONITEC

 **APPROVED**

Recommended for public consultation with a favourable opinion

Brazil



Abiraterone, apalutamide, daralutamide, and enzalutamide

Population:
Adult

11 April 2024



Treatment of metastatic and non-metastatic castration-sensitive prostate cancer.

CONITEC

 **NOTE FROM REPORT**

Recommended for public consultation with a favourable opinion on abiraterone, and with unfavourable opinion on medicines for non-metastatic CRPC and metastatic CRPC

Pharmacological Technologies



Germany  Avapritinib Population: Unknown 02 April 2024	 Treatment of indolent systemic mastocytosis. <i>IQWiG G23-32</i>  APPROVED Orphan drug status	France  Axicabtagene cilocleucel Population: Adult 12 April 2024	 Treatment of relapsed or refractory follicular lymphoma. <i>HAS AP335</i>  APPROVED
England  Cabozantinib with nivolumab Population: Adult 10 April 2024	 Combination treatment of untreated advanced renal cell carcinoma. <i>NICE TA964</i>  APPROVED	Wales  Dabrafenib and trametinib Population: Children >1 year old 24 April 2024	 Combination treatment of BRAF V600E mutation-positive glioma. <i>AWTTC 4995</i>  EXCLUDED Excluded due to NICE appraisal ID5104

Pharmacological Technologies



Germany  Dostarlimab Population: Adult 02 April 2024	 Treatment of advanced or recurrent endometrial cancer. <i>IQWiG A23-143</i> 	Scotland  Dostarlimab Population: Adult 08 April 2024	 Treatment of primary advanced or recurrent endometrial cancer (dMMR/MSI-H). <i>SMC2635</i> 
England  Dostarlimab Population: Adult 03 April 2024	 Treatment of advanced or recurrent endometrial cancer with microsatellite instability or mismatch repair deficiency. <i>NICE TA963</i> 	France  Durvalumab Population: Adult 26 April 2024	 Treatment of non-small cell lung cancer. <i>HAS AP296</i> 

Pharmacological Technologies



Germany



Elranatamab

Population:
Adult

15 April 2024

Treatment of relapsed
or refractory multiple
myeloma.

IQWiG A24-12



Austria



Enzalutamide

Population:
Adult

22 April 2024

Treatment of high-risk
biochemical recurrent
(BCR) non-metastatic
hormone-sensitive
prostate cancer.

AIHTA 170



France



Erdafitinib

Population:
Adult

12 April 2024

Treatment of
unresectable or
metastatic urothelial
carcinoma.

HAS AP293



Austria



Irinotecan
hydrochloride
trihydrate

Population:
Adult

22 April 2024

First-line treatment of
metastatic
adenocarcinoma of the
pancreas.

AIHTA 168



Pharmacological Technologies



Wales  Ivosidenib Population: Unknown 08 April 2024	 First-line treatment in acute myeloid leukaemia, IDH-1, with azacitidine. AWTTC 3680  EXCLUDED Excluded due to NICE appraisal	England  Melphalan flufenamide with dexamethasone Population: Adult 25 April 2024	 Treatment of relapsed or refractory multiple myeloma. NICE TA968  TERMINATED No evidence submitted
Wales  Melphalan flufenamide Population: Adult 25 April 2024	 Treatment of relapsed or refractory multiple myeloma. AWTTC 4081  EXCLUDED Excluded due to NICE appraisal TA968	France  Olaparib Population: Adult 02 April 2024	 Treatment of metastatic castration-resistant prostate cancer (mCRPC). HAS AP173  APPROVED

Pharmacological Technologies



Brazil



Olaparib

Population:
Adult

10 April 2024

Treatment of advanced, newly diagnosed, serous or high-grade endometrioid, BRCA+ ovarian carcinoma.

CONITEC



Recommended for public consultation with an unfavourable opinion

France



Pembrolizumab

Population:
Adult

04 April 2024

Treatment of resectable non-small cell lung cancer.

HAS AP324



France



Pembrolizumab

Population:
Adult

02 April 2024

First-line treatment in unresectable or metastatic bile duct carcinoma.

HAS AP321



England



Pembrolizumab with gemcitabine and cisplatin

Population:
Adult

24 April 2024

Combined treatment of untreated advanced biliary tract carcinoma.

NICE TA966



No evidence submitted

Pharmacological Technologies



Wales  Pembrolizumab Population: Unknown 24 April 2024	 First line treatment in advanced/unresectable cholangiocarcinoma. AWTTC 5017  EXCLUDED Excluded due to NICE appraisal TA966	Germany  Pembrolizumab Population: Adult 02 April 2024	 Treatment of unresectable or metastatic biliary carcinoma. IQWiG A24-03  APPROVED
Germany  Polatumab vedotin Population: Adult 02 April 2024	 First-line treatment in diffuse large B-cell lymphoma. IQWiG A23-141  NOT APPROVED	Germany  Polatumab vedotin Population: Adult 02 April 2024	 Treatment of relapsed or refractory diffuse large B-cell lymphoma. IQWiG A23-140  NOT APPROVED

Pharmacological Technologies



France



Selpercatinib

Population:
Adult

18 April 2024

First-line monotherapy
in advanced non-small
cell lung cancer.

HAS AP325



Austria



Selpercatinib

Population:
Adult

22 April 2024

Treatment of advanced
rearranged during
transfection (RET)
fusion-positive solid
tumours.

AIHTA 169



Wales



Tisagenlecleucel

Population:
Children and
Adolescent
<25 years old

09 April 2024


Treatment of acute
lymphoblastic
leukaemia.

AWTTC 2668



Excluded due to NICE
appraisal

Pharmacological Technologies



Cardiovascular

Scotland



Mavacamten

Population:
Adult

08 April 2024

Treatment of symptomatic (NYHA, class II to III) obstructive hypertrophic cardiomyopathy.

SMC2618



Brazil



Riociguat

Population:
Adult

10 April 2024

Treatment of pulmonary arterial hypertension.

HAS AP300



Treatment of refractory pulmonary arterial hypertension.

CONITEC



Recommended for public consultation with an unfavourable opinion

France



Sotatercept

Population:
Adult


15 April 2024

Treatment of pulmonary arterial hypertension.

HAS AP300



Pharmacological Technologies



Gastrointestinal



Infection

Brazil



Infliximab

Population:
Adult

10 April 2024

Treatment of moderate-to-severe Crohn's disease.

CONITEC



Brazil



Valganciclovir +
ganciclovir

Population:
Unknown
HIV-immunosuppressed
patients

11 April 2024

Combination treatment
of CMV infections.

CONITEC



Recommended for public
consultation with a
favourable opinion

Scotland



Mirikizumab

Population:
Adult

08 April 2024

Treatment of moderate
to severe active
ulcerative colitis.

SMC2650



Pharmacological Technologies



Genetic/Metabolic

Germany



Empagliflozin

Population:
Children and
Adolescent
10 to 17 years

02 April 2024

Treatment of type 2
diabetes.

IQWiG A23-142



Brazil



Inotersen

Population:
Adult

10 April 2024

Treatment of stage 2
familial transthyretin-
mediated amyloid
polyneuropathy.

CONITEC



Recommended for public
consultation with an
unfavourable opinion

France



Lomitapide

Population:
Children and
Adolescent
5 to 17 years old

04 April 2024

Treatment of
homozygous familial
hypercholesterolemia.

HAS AP283



Germany



Pegzilarginase

Population:
Children

15 April 2024

Treatment of
hyperargininaemia.

IQWiG G24-01



Orphan drug status

Pharmacological Technologies



Genetic/Metabolic



Musculoskeletal

Scotland



Tirzepatide

Treatment of type 2 diabetes mellitus.

SMC2633



Population:
Adult

08 April 2024

Brazil



Ixekizumab

Treatment of axial spondyloarthritis, TNFi-refractory.

CONITEC

Population:
Adult

11 April 2024



Recommended for public consultation with an unfavourable opinion

Germany



Vamorolone

Treatment of Duchenne muscular dystrophy.

IQWiG G24-02



Population:
Children

15 April 2024

Orphan drug status

Brazil



Ixekizumab

Treatment of axial spondyloarthritis, anti-inflammatory refractory.

CONITEC

Population:
Adult

11 April 2024



Recommended for public consultation with an unfavourable opinion

Pharmacological Technologies



Neurology

Other

Brazil



Inebilizumab

Population:
Adult

10 April 2024

Treatment of
neuromyelitis optica
spectrum (DENMO) with
AQP4-IgG.

CONITEC



Recommended for public
consultation with an
unfavourable opinion

Scotland



Daridorexant

Population:
Adult

08 April 2024

Treatment of chronic
insomnia.

SMC2611



France



Zilucoplan

Population:
Adult

19 April 2024

Treatment of
myasthenia gravis.

HAS AP138



Pharmacological Technologies



Respiratory

Scotland




Glycopyrronium/
formoterol fumarate

Population:
Adult

08 April 2024

Treatment of chronic
obstructive pulmonary
disease.

SMC2652



Skin

Scotland



Ritlecitinib

Population:
Adult and
Adolescent
>12 years old

08 April 2024

Treatment of severe
alopecia areata.

SMC2610




Non-pharmacological Technologies




Cancer

England  Epidermal radiotherapy with Rhenium-188 paste Population: Unknown 02 April 2024	 Treatment of non-melanoma skin cancer. NICE IPG784  NOT APPROVED	South Korea  Low-temperature circulation method Population: Adult April 2024	 Surgical site analgesia during prostate cancer surgery. NECA  NOT APPROVED
England  Lymphovenous anastomosis Population: Adult 16 April 2024	 During axillary or inguinal node dissection for preventing secondary lymphoedema. NICE IPG785  APPROVED		

Non-pharmacological Technologies



Cardiovascular



Gastrointestinal

South Korea



3D printed artificial blood vessel graft

Population: Unknown

April 2024

Reconstruction of the thoracoabdominal aorta.

NECA

 NOT APPROVED

South Korea



Endoscopic Anti-Reflux Mucosectomy

Population: Unknown

April 2024

Treatment of gastroesophageal reflux disease.

NECA

 APPROVED

South Korea



Resuscitative Endovascular Balloon Occlusion

Population: Adult

April 2024

This technology increases the coronary perfusion pressure for cardiac arrest patients.

NECA

 NOT APPROVED

Further research required

Non-pharmacological Technologies



Genitourinary

England



Diagnosis and management of endometriosis

Population:
Adult

16 April 2024

Changes in the surgical management of endometriosis, if fertility is a priority.

NICE NG73



Mental Health

Spain



Light Therapy

Population:
Adult

April 2024

Treatment of mental health.

OSTEBA



Non-pharmacological Technologies



Musculoskeletal

England



GaitSmart
rehabilitation
exercise programme

Population:
Adult
Adults at risk of falls
or having hip or knee
replacements

03 April 2024

Management of gait and
mobility issues.

NICE MTG78



Neurology

South Korea



Migraine surgery

Population:
Adult

April 2024

Treatment of migraine.

NECA



Non-pharmacological Technologies

Other



Respiratory

South Korea



Portable Automated
Sputum Suction

Population:
Adult

April 2024

Following tracheostomy
or endotracheal
intubation.

NECA



England



Digital pulmonary
rehabilitation
programmes

Population:
Adult

30 April 2024

Management of COPD.

NICE HTE18



Diagnostic Technologies



Cancer



Infection

Spain



Genomic test

Population:
Unknown

April 2024

Cancer risk in lung
nodules when
bronchoscopy is
inconclusive.

OSTEBA



England



Kurin Lock

Population:
Unknown

03 April 2024

Blood culture collection.

NICE MTG77



Diagnostic Technologies



Musculoskeletal

Germany



Fracture
Sonography

Population:
Children

19 April 2024



Suspected fracture of a long tubular bone of the upper extremities.

IQWiG D22-02

 **APPROVED**

Other Guidance



Cancer

Ireland



¹⁷⁷Lutetium PSMA
radioligand therapy

Population:
Adult


26 April 2024

Metastatic castration-
resistant prostate
cancer.

HIQA



EVIDENCE REVIEW



Cardiovascular

Spain



Coronary sinus
reducer stent

Population:
Unknown

April 2024

Refractory angina.

OSTEBA



EVIDENCE REVIEW

Spain



Detection of
mutations

Population:
Adult

April 2024

IDH1 mutations in
cholangiocarcinoma.

AQuAS



EVIDENCE REVIEW

Canada



Renal denervation

Population:
Adult

April 2024

Uncontrolled
hypertension.

CADTH RC1532-000



EVIDENCE REVIEW

Other Guidance



Genetic/Metabolic

Spain



Newborn screening

Population:
Unknown

April 2024

Spinal muscular
atrophy.

AETSA



Musculoskeletal

Spain



Fracture
management

Population:
Adult
Young adult women

April 2024


Prevention of secondary
fractures.

AQUAS



Other Guidance

Other



Skin

United States  Cannabis Population: Unknown April 2024	 Chronic pain. AHRQ  EVIDENCE REVIEW	Canada  Omalizumab Population: Unknown April 2024	 Chronic idiopathic urticaria. CADTH HC0053-000  EVIDENCE REVIEW Drug utilisation study
---	--	--	--

About Us

Crystallise provides an innovative approach to identify and synthesise information, using AI to automate processes and assist our experts to produce deliverables that provide real value to clients.

Our team of researchers, medical writers and copy-editors deliver strategically-relevant and comprehensive written reports as well as visually informative summary slide decks, to suit internal business development, market access, journal publication and health technology assessment submissions.

REVIEWS

Systematic Literature Reviews
Global Value Dossiers
Narrative Reviews
Rapid Reviews
Targeted Reviews

HEALTH ECONOMICS

Return on Investment
Network Meta-Analysis
Budgetary Impact Analysis
Cost-effectiveness Analysis

ACTUARIAL

Risk Management
Pricing & Reserving

MODELLING

Mortality and Morbidity Modelling
Synthetic Sample Generation
Infectious Disease Modelling

[To provide feedback on the HTAngel newsletter, click here.](#)

[To unsubscribe, click here.](#)

Registered address

17 High Street,
Stanford-le-Hope,
Essex, SS17 0HD
+44 (0)1375 517878

Company No: 7980921

Data Protection Act Registration Number: Z3363643

Websites:

www.crystallise.com

www.heoro.com

www.evidencemapper.co.uk